Community-Associated Meticillin-Resistant Staphylococcus aureus Infections Epidemiology, Recognition and Management

被引:40
作者
Patel, Mukesh [1 ,2 ]
机构
[1] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL 35294 USA
[2] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA
关键词
ACQUIRED METHICILLIN-RESISTANT; PANTON-VALENTINE LEUKOCIDIN; SKIN-STRUCTURE INFECTIONS; INDUCIBLE CLINDAMYCIN RESISTANCE; CHROMOSOMAL CASSETTE MEC; MINIMUM INHIBITORY CONCENTRATION; CARE-ASSOCIATED INFECTIONS; SCCMEC TYPE-IV; DOUBLE-BLIND; COMPLICATED SKIN;
D O I
10.2165/00003495-200969060-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Meticillin-resistant Staphylococcus aureus (MRSA) is an important cause of infection, particularly in hospitalized patients and those with significant healthcare exposure. In recent years, epidemic community-associated MRSA (CA-MRSA) infections occurring in patients without healthcare risk factors have become more frequent. The most common manifestation of CA-MRSA infection is skin and soft tissue infection, although necrotizing pneumonia, sepsis and osteoarticular infections can occur. CA-MRSA strains have become endemic in many communities and are genetically distinct from previously identified MRSA strains. CA-MRSA may be more capable colonizers of humans and more virulent than other S. aureus strains. Specific mechanisms of pathogenicity have not been elucidated, but several factors have been proposed as responsible for the virulence of CA-MRSA, including the Panton-Valentine leukocidin, phenol-soluble modulins and type I arginine catabolic mobile element. The movement of CA-MRSA strains into the nosocomial setting limits the utility of using clinical risk factors alone to designate community- or healthcare-associated status. Identification of unique genetic characteristics and genotyping are valuable tools for MRSA epidemiological studies. Although the optimum pharmacological therapy for CA-MRSA infections has not been determined, many CA-MRSA strains remain broadly susceptible to several non-p-lactam antibacterial agents. Empirical antibacterial therapy should include an MRSA-active agent, particularly in areas where CA-MRSA is endemic.
引用
收藏
页码:693 / 716
页数:24
相关论文
共 214 条
[1]   Brief report:: Staphylococcus aureus sepsis and the waterhouse-friderichsen syndrome in children [J].
Adem, PV ;
Montgomery, CP ;
Husain, AN ;
Koogler, TK ;
Arangelovich, V ;
Humilier, M ;
Boyle-Vavra, S ;
Daum, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (12) :1245-1251
[2]  
[Anonymous], 2003, MORBIDITY MORTALITY, V52, P992
[3]  
[Anonymous], 1999, MMWR, V48, P707
[4]  
[Anonymous], 2003, MMWR, V52, P793
[5]   The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].
Arbeit, RD ;
Maki, D ;
Tally, FP ;
Campanaro, E ;
Eisenstein, BI .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681
[6]   Changing patterns of acute hematogenous osteomyelitis and septic arthritis - Emergence of community-associated methicillin-resistant Staphylococcus aureus [J].
Arnold, Sandra R. ;
Elias, David ;
Buckingham, Steven C. ;
Thomas, Eddie D. ;
Novais, Eduardo ;
Arkader, Alexandre ;
Howard, Cassandra .
JOURNAL OF PEDIATRIC ORTHOPAEDICS, 2006, 26 (06) :703-708
[7]  
ARPIDA AG, NCT00299520 US NIH
[8]  
ARPIDA AG, NCT00543608 US NIH
[9]  
ARPIDA AG, NCT00303550 US NIH
[10]   Genome and virulence determinants of high virulence community-acquired MRSA [J].
Baba, T ;
Takeuchi, F ;
Kuroda, M ;
Yuzawa, H ;
Aoki, K ;
Oguchi, A ;
Nagai, Y ;
Iwama, N ;
Asano, K ;
Naimi, T ;
Kuroda, H ;
Cui, L ;
Yamamoto, K ;
Hiramatsu, K .
LANCET, 2002, 359 (9320) :1819-1827